Kristen J. Bubb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristen J. Bubb has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Stephen J. Nicholls
Victorian Heart Institute, School of Clinical Sciences, Monash University, Victorian Heart Hospital, 631 Blackburn Rd, Clayton, 3168, Australia
4 shared publications- Beth Joyce Allison
The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Australia
3 shared publications - Gemma Alexandra Figtree
School of Medical Sciences, Faculty of Medicine and Health, University of Sydney , Camperdown, NSW 2006
3 shared publications Giannie Barsha
Monash University
3 shared publications- Graeme R. Polglase
Department of Paediatrics Monash University Melbourne Victoria Australia
3 shared publications - Stephen J. Nicholls
Victorian Heart Institute, Monash University, Clayton, Australia
3 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by ScienceOpen
C-type natriuretic peptide reduces blood pressure and restores placental angiogenesis in a mouse model of preeclampsia
- 13 April 2026
- Published by ScienceOpen
Open AccessC-type natriuretic peptide reduces blood pressure and restores placental angiogenesis in a mouse model of preeclampsia
- Open Access
Eicosapentaenoic Acid Enhances Angiogenesis and Reperfusion After Ischemia: Comparative Effects of Omega-3 Fatty Acids in a Murine Hind Limb Model
Background: Omega-3 polyunsaturated fatty acids are known to confer benefits in the prevention of cardiovascular diseases. Among these, eicosapentaenoic acid (EPA) appears to be more effective than docosahexaenoic acid (DHA) in ischemic vascular conditions. However, the specific roles of EPA and DHA in limb angiogenesis and post-ischemic reperfusion remain unclear. Moreover, omega-3 fatty acids remain understudied for peripheral artery disease (PAD) intervention. The aim was to compare the effect of high dose omega-3 fatty acids, EPA and DHA on ischemic tissue reperfusion, angiogenesis and vascular remodelling in mice. Methods: Hind limb ischemia (HLI) was performed in mice and reperfusion was measured using laser speckle contrast imaging over two weeks post-HLI. Mice were treated daily with oral high-dose EPA or DHA (600 mg/kg/day) or vehicle (olive oil). Gastrocnemius muscle tissue was collected for analysis of mRNA and protein markers of angiogenesis. Results: Following HLI, blood flow was restored more rapidly in mice treated with EPA compared with vehicle. DHA treatment did not enhance reperfusion. Histological assessment revealed significant muscle fibre regeneration after HLI, which was further improved by EPA. CD31+ neo vessel density was also increased in the EPA group. Collectively, these findings indicate that EPA promotes angiogenesis after peripheral vascular ischemia, whereas DHA does not. The beneficial effects of EPA are associated with upregulation of hypoxia inducible factor α. Conclusions: High-dose EPA accelerated post-ischemic reperfusion, while DHA was ineffective. These results highlight EPA as a potential therapeutic strategy for improving limb perfusion and vascular repair in patients with PAD. Research Perspective: What Is New?: Omega-3 fatty acid, eicosapentaenoic acid (EPA) accelerates post-ischaemic reperfusion following hind limb ischemia injury in mice. Omega 3 fatty acid, docosahexaenoic acid (DHA), does not show the same improvement in reperfusion after hind limb ischemia EPA can promote vasculogenesis and stimulate muscle fibre regeneration. What question should be addressed next?: High dose purified EPA, in the form of icosapent ethyl reduces mortality from coronary artery disease. Peripheral artery disease (PAD) is a common co-morbidity yet high quality interventional trials for icosapent ethyl for PAD are lacking. Therapeutic angiogenesis has the potential to improve PAD symptoms and disease progression but there are no efficacious candidates. Icosapent ethyl should be trialled to determine whether functional outcomes are improved in PAD.
Open AccessEicosapentaenoic Acid Enhances Angiogenesis and Reperfusion After Ischemia: Comparative Effects of Omega-3 Fatty Acids in a Murine Hind Limb Model
Background: Omega-3 polyunsaturated fatty acids are known to confer benefits in the prevention of cardiovascular diseases. Among these, eicosapentaenoic acid (EPA) appears to be more effective than docosahexaenoic acid (DHA) in ischemic vascular conditions. However, the specific roles of EPA and DHA in limb angiogenesis and post-ischemic reperfusion remain unclear. Moreover, omega-3 fatty acids remain understudied for peripheral artery disease (PAD) intervention. The aim was to compare the effect of high dose omega-3 fatty acids, EPA and DHA on ischemic tissue reperfusion, angiogenesis and vascular remodelling in mice. Methods: Hind limb ischemia (HLI) was performed in mice and reperfusion was measured using laser speckle contrast imaging over two weeks post-HLI. Mice were treated daily with oral high-dose EPA or DHA (600 mg/kg/day) or vehicle (olive oil). Gastrocnemius muscle tissue was collected for analysis of mRNA and protein markers of angiogenesis. Results: Following HLI, blood flow was restored more rapidly in mice treated with EPA compared with vehicle. DHA treatment did not enhance reperfusion. Histological assessment revealed significant muscle fibre regeneration after HLI, which was further improved by EPA. CD31+ neo vessel density was also increased in the EPA group. Collectively, these findings indicate that EPA promotes angiogenesis after peripheral vascular ischemia, whereas DHA does not. The beneficial effects of EPA are associated with upregulation of hypoxia inducible factor α. Conclusions: High-dose EPA accelerated post-ischemic reperfusion, while DHA was ineffective. These results highlight EPA as a potential therapeutic strategy for improving limb perfusion and vascular repair in patients with PAD. Research Perspective: What Is New?: Omega-3 fatty acid, eicosapentaenoic acid (EPA) accelerates post-ischaemic reperfusion following hind limb ischemia injury in mice. Omega 3 fatty acid, docosahexaenoic acid (DHA), does not show the same improvement in reperfusion after hind limb ischemia EPA can promote vasculogenesis and stimulate muscle fibre regeneration. What question should be addressed next?: High dose purified EPA, in the form of icosapent ethyl reduces mortality from coronary artery disease. Peripheral artery disease (PAD) is a common co-morbidity yet high quality interventional trials for icosapent ethyl for PAD are lacking. Therapeutic angiogenesis has the potential to improve PAD symptoms and disease progression but there are no efficacious candidates. Icosapent ethyl should be trialled to determine whether functional outcomes are improved in PAD.
- Open Access
- 23 December 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (24) , 1709-1732
In vivo and ex vivo cardiovascular haemodynamic responses of preterm growth-restricted lambs to perinatal asphyxia
Fetal growth restriction (FGR) arises from chronic hypoxia and increases the risk of cardiovascular dysfunction following perinatal asphyxia, although underlying mechanisms remain unclear. We investigated whether cardiovascular responses to asphyxia are impaired in preterm FGR lambs and whether this arises from α1- and β1-adrenergic receptor dysfunction. Ewes underwent sterile fetal surgery at 89 days’ gestation (d; term=148 d) to induce FGR (single umbilical artery ligation) or sham surgery (control). At 126 d, lambs were delivered, instrumented and randomised to immediate ventilation (ControlVENTn=6; FGRVENTn=6) or asphyxia (ControlASPHYXIAn=12; FGRASPHYXIAn=11) by umbilical cord occlusion until diastolic blood pressure (BP) decreased to 10 mmHg. Lambs were ventilated for 8 hours before baseline ex vivo cardiac function was assessed via Langendorff perfusion to measure left ventricular developed pressure (LVDP), heart rate (HR) and coronary perfusion pressure (CPP). Ex vivo α1- and β1-adrenergic responses were assessed via phenylephrine and dobutamine administration, respectively. FGRASPHYXIA lambs had lower BP during asphyxia and took longer to reach a diastolic BP of 10 mmHg (P<0.05 vs ControlASPHYXIA). FGRASPHYXIA lambs had lower BP in the first 5 minutes after return of spontaneous circulation due to impaired vascular contractility (P<0.05 vs ControlASPHYXIA). Baseline LVDP, HR and CPP were similar between groups. FGRASPHYXIA lambs had increased LVDP responses to phenylephrine and dobutamine (P<0.05 vs FGRVENT and ControlASPHYXIA), without significant changes to HR or CPP. Overall, FGR lambs exhibit impaired vascular contractility and heightened cardiac α1- and β1-adrenergic responsiveness after perinatal asphyxia, consistent with reduced autonomic regulation, potentially increasing susceptibility to cardiovascular dysfunction postnatally.
- 23 December 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (24) , 1709-1732
Open AccessIn vivo and ex vivo cardiovascular haemodynamic responses of preterm growth-restricted lambs to perinatal asphyxia
Fetal growth restriction (FGR) arises from chronic hypoxia and increases the risk of cardiovascular dysfunction following perinatal asphyxia, although underlying mechanisms remain unclear. We investigated whether cardiovascular responses to asphyxia are impaired in preterm FGR lambs and whether this arises from α1- and β1-adrenergic receptor dysfunction. Ewes underwent sterile fetal surgery at 89 days’ gestation (d; term=148 d) to induce FGR (single umbilical artery ligation) or sham surgery (control). At 126 d, lambs were delivered, instrumented and randomised to immediate ventilation (ControlVENTn=6; FGRVENTn=6) or asphyxia (ControlASPHYXIAn=12; FGRASPHYXIAn=11) by umbilical cord occlusion until diastolic blood pressure (BP) decreased to 10 mmHg. Lambs were ventilated for 8 hours before baseline ex vivo cardiac function was assessed via Langendorff perfusion to measure left ventricular developed pressure (LVDP), heart rate (HR) and coronary perfusion pressure (CPP). Ex vivo α1- and β1-adrenergic responses were assessed via phenylephrine and dobutamine administration, respectively. FGRASPHYXIA lambs had lower BP during asphyxia and took longer to reach a diastolic BP of 10 mmHg (P<0.05 vs ControlASPHYXIA). FGRASPHYXIA lambs had lower BP in the first 5 minutes after return of spontaneous circulation due to impaired vascular contractility (P<0.05 vs ControlASPHYXIA). Baseline LVDP, HR and CPP were similar between groups. FGRASPHYXIA lambs had increased LVDP responses to phenylephrine and dobutamine (P<0.05 vs FGRVENT and ControlASPHYXIA), without significant changes to HR or CPP. Overall, FGR lambs exhibit impaired vascular contractility and heightened cardiac α1- and β1-adrenergic responsiveness after perinatal asphyxia, consistent with reduced autonomic regulation, potentially increasing susceptibility to cardiovascular dysfunction postnatally.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1633-H1645
Untargeted metabolomics identifies altered cardiac metabolite and gene expression patterns in late preterm growth-restricted newborn lambs
Within 24 h of birth, growth-restricted (FGR) newborn lambs exhibited altered lipid and serotonin metabolites, suggesting disrupted postnatal cardiac metabolic adaptation. Despite upregulation of the fatty acid transporter gene SLC27A6, with other fatty acid oxidation genes remaining largely unchanged, reductions in lipid and carnitine metabolites indicate potential impairments in fatty acid utilization. Decreased serotonin bioavailability further suggests metabolic reprogramming in FGR hearts, highlighting the need for future studies on the implications for postnatal cardiac function.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1633-H1645
Untargeted metabolomics identifies altered cardiac metabolite and gene expression patterns in late preterm growth-restricted newborn lambs
Within 24 h of birth, growth-restricted (FGR) newborn lambs exhibited altered lipid and serotonin metabolites, suggesting disrupted postnatal cardiac metabolic adaptation. Despite upregulation of the fatty acid transporter gene SLC27A6, with other fatty acid oxidation genes remaining largely unchanged, reductions in lipid and carnitine metabolites indicate potential impairments in fatty acid utilization. Decreased serotonin bioavailability further suggests metabolic reprogramming in FGR hearts, highlighting the need for future studies on the implications for postnatal cardiac function.
- 24 October 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (1) , 104417
Response to comments on “The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis”
- 24 October 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (1) , 104417
Response to comments on “The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis”
- Open Access
- 22 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71058
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Apolipoprotein C3 (ApoC3) regulates triglyceride metabolism and is associated with accelerated atherogenesis and adverse cardiovascular outcomes. However, its role in peripheral artery disease (PAD) remains unclear. We investigated whether Apoc3 deficiency impacts key features of PAD. Vascularization was assessed using an inflammatory periarterial cuff model (21 days) and a hind limb ischemia model (14 days) in male and female Apoc3 +/+ and Apoc3 −/− mice. Neovascularization was also assessed in mice following extracellular matrix (ECM) plug implantation. Isolated human umbilical vein endothelial cells (HUVECs) were co‐cultured with ApoC3‐stimulated THP‐1 monocytes, and tubule formation was assessed. Apoc3 ‐deficient mice demonstrated less neovessel formation around the cuffed femoral artery, with endothelial cell (CD31+) staining reduced by approximately 40% compared to Apoc3 +/+ mice. Twenty‐four hours after cuff placement, Apoc3 +/+ vessels exhibited increased expression of angiogenic ( Hif1a and Vegf1 ) and pro‐inflammatory ( Cd68 ) markers, while Apoc3 ‐deficient vessels did not. Confirming a role for inflammation in ApoC3‐induced angiogenesis, tubulogenesis of HUVECs increased only in the presence of ApoC3 and THP‐1 monocytes. Apoc3 deficiency, however, did not affect ischemia‐driven angiogenesis, as there were no differences in revascularization compared to Apoc3 +/+ mice, as assessed by the perfusion index (laser Doppler), fibrosis (Picrosirius red staining), or the mRNA expression of apoptotic ( Bax ), angiogenic ( Hif1a and Vegf1 ), and inflammatory ( Ccl2 , Il6 , and Vcam1 ) markers in the ischemic hind limb. Neovascularization following ECM plug implantation was also unaffected by Apoc3 deficiency. In conclusion, ApoC3 contributes to pathological, inflammation‐driven angiogenesis, highlighting its potential as a therapeutic target for pathological angiogenesis without inhibiting physiological ischemia‐driven angiogenesis.
- 22 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71058
Open AccessApolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Apolipoprotein C3 (ApoC3) regulates triglyceride metabolism and is associated with accelerated atherogenesis and adverse cardiovascular outcomes. However, its role in peripheral artery disease (PAD) remains unclear. We investigated whether Apoc3 deficiency impacts key features of PAD. Vascularization was assessed using an inflammatory periarterial cuff model (21 days) and a hind limb ischemia model (14 days) in male and female Apoc3 +/+ and Apoc3 −/− mice. Neovascularization was also assessed in mice following extracellular matrix (ECM) plug implantation. Isolated human umbilical vein endothelial cells (HUVECs) were co‐cultured with ApoC3‐stimulated THP‐1 monocytes, and tubule formation was assessed. Apoc3 ‐deficient mice demonstrated less neovessel formation around the cuffed femoral artery, with endothelial cell (CD31+) staining reduced by approximately 40% compared to Apoc3 +/+ mice. Twenty‐four hours after cuff placement, Apoc3 +/+ vessels exhibited increased expression of angiogenic ( Hif1a and Vegf1 ) and pro‐inflammatory ( Cd68 ) markers, while Apoc3 ‐deficient vessels did not. Confirming a role for inflammation in ApoC3‐induced angiogenesis, tubulogenesis of HUVECs increased only in the presence of ApoC3 and THP‐1 monocytes. Apoc3 deficiency, however, did not affect ischemia‐driven angiogenesis, as there were no differences in revascularization compared to Apoc3 +/+ mice, as assessed by the perfusion index (laser Doppler), fibrosis (Picrosirius red staining), or the mRNA expression of apoptotic ( Bax ), angiogenic ( Hif1a and Vegf1 ), and inflammatory ( Ccl2 , Il6 , and Vcam1 ) markers in the ischemic hind limb. Neovascularization following ECM plug implantation was also unaffected by Apoc3 deficiency. In conclusion, ApoC3 contributes to pathological, inflammation‐driven angiogenesis, highlighting its potential as a therapeutic target for pathological angiogenesis without inhibiting physiological ischemia‐driven angiogenesis.
- Open Access
- 15 September 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 6695-6717
Compromised cardiopulmonary transition in fetal growth restricted and small for gestational age neonates
The cardiopulmonary transition at birth is a critical physiological process requiring coordinated cardiovascular adaptation to meet the increased circulatory demands of extrauterine life. This transition may be compromised in infants affected by suboptimal fetal growth, such as in infants born small for gestational age (SGA) or classified with fetal growth restriction (FGR). Suboptimal fetal growth often arises from reduced oxygen and nutrient supply, leading to prioritised perfusion of crucial organs and subsequent cardiac and arterial remodelling. These cardiovascular adaptations, while necessary for fetal survival, may persist postnatally and increase the risk of an impaired cardiovascular transition at birth. Altered echocardiographic function and cardiac injury biomarkers are often detectable in this population during the early postnatal period, indicating underlying myocardial stress and a predisposition to an impaired transition. FGR and/or SGA neonates often exhibit impaired diastolic function, reflecting impaired myocardial relaxation and reduced compliance, and systolic dysfunction, including a reduced capacity to increase left ventricular output over time. Additionally, elevated pulmonary vascular resistance contributes to an increased risk of respiratory morbidity. Emerging preclinical data suggest that these adaptations may impede the neonate's ability to respond to perinatal stressors, thus increasing the risk of adverse outcomes. Understanding the multifaceted nature of cardiovascular dysfunction in FGR and/or SGA infants during the perinatal period is essential to improving their long‐term outcomes, thus reducing the risk of cardiovascular disease later in life. image
- 15 September 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 6695-6717
Open AccessCompromised cardiopulmonary transition in fetal growth restricted and small for gestational age neonates
The cardiopulmonary transition at birth is a critical physiological process requiring coordinated cardiovascular adaptation to meet the increased circulatory demands of extrauterine life. This transition may be compromised in infants affected by suboptimal fetal growth, such as in infants born small for gestational age (SGA) or classified with fetal growth restriction (FGR). Suboptimal fetal growth often arises from reduced oxygen and nutrient supply, leading to prioritised perfusion of crucial organs and subsequent cardiac and arterial remodelling. These cardiovascular adaptations, while necessary for fetal survival, may persist postnatally and increase the risk of an impaired cardiovascular transition at birth. Altered echocardiographic function and cardiac injury biomarkers are often detectable in this population during the early postnatal period, indicating underlying myocardial stress and a predisposition to an impaired transition. FGR and/or SGA neonates often exhibit impaired diastolic function, reflecting impaired myocardial relaxation and reduced compliance, and systolic dysfunction, including a reduced capacity to increase left ventricular output over time. Additionally, elevated pulmonary vascular resistance contributes to an increased risk of respiratory morbidity. Emerging preclinical data suggest that these adaptations may impede the neonate's ability to respond to perinatal stressors, thus increasing the risk of adverse outcomes. Understanding the multifaceted nature of cardiovascular dysfunction in FGR and/or SGA infants during the perinatal period is essential to improving their long‐term outcomes, thus reducing the risk of cardiovascular disease later in life. image
- Open Access
- 30 August 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (1) , 104286
The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis
- 30 August 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 36 (1) , 104286
Open AccessThe effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis
- 16 July 2025
- Published by Elsevier in Atherosclerosis
- Vol. 408, 120425
Fuelling the Switch: AK4 is a master energy regulator of vascular smooth muscle cell fate
- 16 July 2025
- Published by Elsevier in Atherosclerosis
- Vol. 408, 120425
Fuelling the Switch: AK4 is a master energy regulator of vascular smooth muscle cell fate
- Open Access
- 5 October 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 984, 177031
Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk
- 5 October 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 984, 177031
Open AccessUnique cardiometabolic factors in women that contribute to modified cardiovascular disease risk